Fortress Biotech 2023 rev $84.5M; net loss $(68.7)M; DFD-29 PDUFA Nov 4, 2024

Fortress Biotech, Inc.

Record consolidated net revenue $84.5M in 2023, up from $75.7M in 2022; net loss $(68.7)M ($8.47/share) vs $(94.6)M ($15.97).
Cash $83.4M at Dec 31, 2023, down $97.6M YoY; raised ~$34.9M in 2023/early 2024 offerings.
FDA accepted DFD-29 NDA for rosacea; PDUFA date Nov 4, 2024; up to 4 NDA/BLA decisions in next 18 months.
Cosibelimab BLA received CRL in Dec 2023 (manufacturing only); resubmission expected for 2024 approval.
Journey Medical product net revenues fell to $59.7M from $71.0M; total net rev $79.2M (+7%).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Fortress Biotech, Inc. reported the full year ended December 31, 2023 results: revenue Record consolidated net revenue of $84.5 million.

Period: the full year ended December 31, 2023
Revenue: Record consolidated net revenue of $84.5 million
Result: reported results

Exact text from the filing

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Fortress Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-040521

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.